A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19.

点击翻译按钮获取中文摘要

The primary objective of this study is to evaluate the safety and early clinical efficacy of fostamatinib following allogeneic BM transplantation in patients with post transplant immune mediated cytopenias. This trial is the extension arm of the primary trial, with enrollment reserved for those responding to fostamatinib treatment on the primary trial. Secondary objectives will be to assess clinically relevant endpoints of safety. Subject Inclusion and Exclusion Criteria will be reviewed as appropriate by a member of the study team. If there is any uncertainty, the PI should make the decision on whether a potential subject is eligible for study enrollment. Certain human subjects are categorized as vulnerable populations and require special treatment with respect to safeguards of their well-being. For this clinical trial, examples include cognitively impaired or mentally disabled persons and intubated individuals who are sedated. When it is determined that a potential research subject is cognitively impaired, federal and institutional regulations permit researchers to obtain consent from a legally authorized representative (LAR). The study team will obtain consent from these vulnerable subjects using an IRB-approved protocol- specific process for consent using a LAR.